Image 1-XPOVIO (selinexor) - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Image 1-XPOVIO (selinexor)
XPOVIO® (selinexor) is the only oral therapy indicated for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL). Credit: Karyopharm Therapeutics Inc.